EntryPoint Capital LLC Takes Position in Alphatec Holdings, Inc. $ATEC

Key Points

• EntryPoint Capital LLC invested $256,000 in Alphatec Holdings, purchasing 25,210 shares, indicating institutional interest in the medical technology company.
• Alphatec's stock has seen significant activity, with hedge funds modifying their positions; for instance, Wealth Enhancement Advisory increased its stake by 301.0%.
• Analysts have recently upgraded Alphatec's rating from "hold" to "buy," with price targets set as high as $22.00, reflecting positive sentiment about the company’s growth prospects.

EntryPoint Capital LLC purchased a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 25,210 shares of the medical technology company's stock, valued at approximately $256,000.

Other institutional investors have also made changes to their positions in the company. Comerica Bank boosted its stake in shares of Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after buying an additional 1,248 shares during the period. Quarry LP lifted its stake in Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after purchasing an additional 2,375 shares during the last quarter. Larson Financial Group LLC bought a new stake in Alphatec during the first quarter worth $54,000. Lazard Asset Management LLC bought a new stake in Alphatec during the fourth quarter worth $76,000. Finally, State of Wyoming bought a new stake in Alphatec during the fourth quarter worth $86,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Trading Down 1.9%

NASDAQ ATEC traded down $0.30 on Monday, reaching $15.84. The company had a trading volume of 1,536,977 shares, compared to its average volume of 3,222,100. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The business has a 50 day moving average of $12.47 and a two-hundred day moving average of $11.60. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $16.47. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -14.02 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The firm had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. During the same period last year, the business posted ($0.29) EPS. The business's revenue was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. Analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ATEC shares. Barclays restated an "overweight" rating and set a $22.00 target price (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 price target for the company in a research note on Monday, June 16th. Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research note on Friday, August 1st. Wall Street Zen upgraded Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $18.50.

Insiders Place Their Bets

In other news, General Counsel Tyson Eliot Marshall sold 18,092 shares of the firm's stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total value of $269,751.72. Following the completion of the sale, the general counsel directly owned 438,331 shares in the company, valued at $6,535,515.21. This trade represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Craig E. Hunsaker sold 10,876 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $15.33, for a total value of $166,729.08. Following the completion of the sale, the executive vice president owned 1,389,142 shares of the company's stock, valued at approximately $21,295,546.86. This represents a 0.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 410,247 shares of company stock worth $5,376,804. Company insiders own 22.80% of the company's stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.